Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: Opportunities and obstacles for survival signaling

British Journal of Pharmacology

Volumn 152, Issue 6, 2007, Pages 855-869

  Burley, D S ^a   Ferdinandy, P ^b   Baxter, G F ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Atrial natriuretic peptide; B type natriuretic peptide; CGMP dependent protein kinase; Cyclic guanosine 3 ,5 monophosphate; Myocardial infarction; Nitric oxide; Nitric oxide synthase; Particulate guanylate cyclase; Soluble guanylate cyclase

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CHELERYTHRINE; CICLETANINE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; GLIBENCLAMIDE; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KT 5823; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC FACTOR; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEIN KINASE B; RHO KINASE INHIBITOR; SILDENAFIL; TETRAPHENYLPHOSPHONIUM; UNINDEXED DRUG; URODILATIN; VARDENAFIL; ZAPRINAST;

CALCIUM TRANSPORT; CARDIOVASCULAR SYSTEM; CELL COMPARTMENTALIZATION; CELL DEATH; CELL SURVIVAL; CELLULAR DISTRIBUTION; DRUG EFFECT; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBSTRATE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HOMEOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CELL SURVIVAL; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; HUMANS; MYOCARDIAL REPERFUSION INJURY; NATRIURETIC PEPTIDES; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 35348870623     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707409     Document Type: Review

References (165)

1. 2+ storage. Cardiovasc Res 70: 346-353.
2. Abdallah Y, Gkatzoflia A, Pieper H, Zoga E, Walther S, Kasseckert S et al. (2005). Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury. Cardiovasc Res 66: 123-131.
3. Abrams J (1996). Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol 77: 31-37.
4. Agullo L, Garcia-Dorado D, Escalona N, Ruiz-Meana M, Inserte J, Soler-Soler J (2003). Effect of ischemia on soluble and particulate guanylyl cyclase-mediated cGMP synthesis in cardiomyocytes. Am J Physiol Heart Circ Physiol 284: 2170-2176.
5. Allen BS, Buckberg GD, Fontan FM, Kirsh MM, Popoff G, Beyersdorf F et al. (1993). Superiority of controlled surgical reperfusion versus percutaneous transluminal coronary angioplasty in acute coronary occlusion. J Thorac Cardiovasc Surg 105: 864-879.
6. Anand-Srivastava MB (2005). Natriuretic peptide receptor-C signaling and regulation. Peptides 26: 1044-1059.
7. ATP increases superoxide generation from complex I of the electron transport chain. Am J Physiol 291: 2041-2043.
8. Ashman DF, Lipton R, Melicow MM, Price TD (1963). Isolation of adenosine 3′, 5′-monophosphate and guanosine 3′, 5′-monophosphate from rat urine. Biochem Biophys Res Commun 11: 330-334.
9. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S et al. (2006). Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290: 1960-1968.
10. Baxter GF, Ebrahim Z (2002). Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol 135: 843-854.
11. Bell RM, Maddock HL, Yellon DM (2003). The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. Cardiovasc Res 57: 405-415.
12. Bell RM, Yellon DM (2003a). Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41: 508-515.
13. Bell RM, Yellon DM (2003b). Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35: 185-193.
14. Bolli R (2001). Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33: 1897-1918.
15. Bolli R, Manchikalapudi S, Tang XL, Takano H, Qiu Y, Guo Y et al. (1997). The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res 81: 1094-1107.
16. Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC (2005). Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res 57: 22-27.
17. Burley DS, Baxter GF (2005). Post-conditioning is dependent on PKG activation in early reperfusion. J Mol Cell Cardiol 38: 1008 (abstract).
18. Burley DS, Baxter GF (2007). B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol (in press).
19. Burley DS, Hamid SA, Baxter GF (2007). Cardioprotective actions of peptide hormones inmyocardial ischemia. Heart Fail Rev 12: 279-291.
20. Burnett AL (2005). Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol 96: 29-31.
21. Choi BM, Pae HO, Jang SI, Kim YM, Chung HT (2002). Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J Biochem Mol Biol 35: 116-126.
22. Cohen MV, Yang XM, Downey JM (2006). Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res 70: 231-239.
23. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV et al. (2005). Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97: 329-336.
24. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD (2006). The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 281: 20801-20808.
25. Csont T, Csonka C, Kovacs P, Jancso G, Ferdinandy P (2003). Capsaicin-sensitive sensory neurons regulate myocardial nitric oxide and cGMP signaling. Eur J Pharmacol 476: 107-113.
26. Csont T, Ferdinandy P (2005). Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 105: 57-68.
27. Csont T, Pali T, Szilvassy Z, Ferdinandy P (1998). Lack of correlation between myocardial nitric oxide and cyclic guanosine monophosphate content in both nitrate-tolerant and -nontolerant rats. Biochem Pharmacol 56: 1139-1144.
28. Cuong DV, Kim N, Youm JB, Joo H, Warda M, Lee JW et al. (2006). Nitric oxide-cGMP-protein kinase G signaling pathway induces anoxic preconditioning through activation of ATP-sensitive K+ channels in rat hearts. Am J Physiol Heart Circ Physiol 290: 1808-1817.
29. Czarnowska E, Kurzelewski M, Beresewicz A, Karczmarewicz E (2001). The role of endogenous nitric oxide in inhibition of ischemia/reperfusion-induced cardiomyocyte apoptosis. Folia Histochem Cytobiol 39: 179-180.
30. Das A, Smolenski A, Lohmann SM, Kukreja RC (2006). Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J Biol Chem 281: 38644-38652.
31. Dawn B, Bolli R (2002). Role of nitric oxide in myocardial preconditioning. Ann NY Acad Sci 962: 18-41.
32. Depre C, Hue L (1994). Cyclic GMP in the perfused rat heart. Effect of ischaemia, anoxia and nitric oxide synthase inhibitor. FEBS Lett 345: 241-245.
33. + and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276: 2571-2575.
34. Downey JM, Cohen MV (2006). Reducing infarct size in the setting of acute myocardial infarction. Prog Cardiovasc Dis 48: 363-371.
35. D'Souza SP, Davis M, Baxter GF (2004). Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 101: 113-129.
36. ATP channel opening. Am J Physiol Heart Circ Physiol 284: 1592-1600.
37. du Toit EF, Genade S, Carlini S, Moolman JA, Brunner F, Lochner A (2007). Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model. Eur J Pharmacol 556: 115-120.
38. Efthymiou CA, Mocanu MM, Yellon DM (2005). Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45: 247-252.
39. Feil R, Kemp-Harper B (2006). cGMP signalling: from bench to bedside. EMBO Rep 7: 149-153.
40. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F (2003). Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 93: 907-916.
41. Ferdinandy P, Schulz R (2003). Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543.
42. Ferdinandy P, Szilvassy Z, Baxter GF (1998). Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon? Trends Pharmacol Sci 19: 223-229.
43. Fiscus RR, Yuen JP, Chan SL, Kwong JH, Chew SB (2002). Nitric oxide and cyclic GMP as pro- and anti-apoptotic agents. J Card Surg 17: 336-339.
44. Friebe A, Koesling D (2003). Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93: 96-105.
45. Ca channels expressed in mammalian cells by direct phosphorylation at serine 1072. J Biol Chem 274: 10927-10935.
46. Gateau-Roesch O, Argaud L, Ovize M (2006). Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 70: 264-273.
47. Gerassimou C, Kotanidou A, Zhou Z, Simoes DC, Roussos C, Papapetropoulos A (2007). Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species. Br J Pharmacol 150: 1084-1091.
48. 2 Online (abstract).
49. Giricz Z, Gorbe A, Burley DS, Pipis J, Ferdinandy P, Baxter GF (2006). cGMP-dependent protein kinase mediates protection against ischaemia-reperfusion injury. J Mol Cell Cardiol 40: 961 (abstract).
50. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM (1995). Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77: 611-621.
51. Gourine AV, Bulhak AA, Gonon AT, Pernow J, Sjoquist PO (2002). Cardioprotective effect induced by brief exposure to nitric oxide before myocardial ischemia-reperfusion in vivo. Nitric Oxide 7: 210-216.
52. Guo Y, Stein AB, Wu WJ, Zhu X, Tan W, Li Q et al. (2005). Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Circ Physiol 289: 2251-2257.
53. Halestrap AP, Clarke SJ, Javadov SA (2004). Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res 61: 372-385.
54. Hamid SA, Baxter GF (2005). Adrenomedullin limits reperfusion injury in experimental myocardial infarction. Basic Res Cardiol 100: 387-396.
55. Hamid SA, Baxter GF (2006). A critical cytoprotective role of endogenous adrenomedullin in acute myocardial infarction. J Mol Cell Cardiol 41: 360-363.
56. Hamid SA, Bower HS, Baxter GF (2007a). Rho-kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292: H2598-H2606.
57. Hamid SA, Totzeck M, Drexhage C, Thompson I, Fowkes RC, Rassaf T et al. (2007b). NO/cGMP pathway in adrenomedullin-mediated cardioprotection in mouse. J Mol Cell Cardiol 42 (suppl 1): S195 (abstract).
58. Hart CY, Hahn EL, Meyer DM, Burnett Jr JC, Redfield MM (2001). Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs. Am J Physiol Heart Circ Physiol 281: 146-154.
59. Hausenloy DJ, Mocanu MM, Yellon DM (2004). Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 63: 305-312.
60. Hausenloy DJ, Tsang A, Yellon DM (2005). The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15: 69-75.
61. Hausenloy DJ, Yellon DM (2004). New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61: 448-460.
62. Hausenloy DJ, Yellon DM (2006). Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70: 240-253.
63. Hempel A, Friedrich M, Schluter KD, Forssmann WG, Kuhn M, Piper HM (1997). ANP protects against reoxygenation-induced hypercontracture in adult cardiomyocytes. Am J Physiol 273: 244-249.
64. Heusch G (2004). Postconditioning: old wine in a new bottle? J Am Coll Cardiol 44: 1111-1112.
65. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A (2004). Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 110: 1231-1235.
66. Horimoto H, Gaudette GR, Saltman AE, Krukenkamp IB (2000). The role of nitric oxide, K(+)(ATP) channels, and cGMP in the preconditioning response of the rabbit. J Surg Res 92: 56-63.
67. Huang J, Mahavadi S, Sriwai W, Hu W, Murthy KS (2006). Gi-coupled receptors mediate phosphorylation of CPI-17 and MLC20 via preferential activation of the PI3K/ILK pathway. Biochem J 396: 193-200.
68. Hussain MB, MacAllister RJ, Hobbs AJ (2001). Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol 280: H1151-H1159.
69. Inserte J, Garcia-Dorado D, Agullo L, Paniagua A, Soler-Soler J (2000). Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res 45: 351-359.
70. Inserte J, Garcia-Dorado D, Ruiz-Meana M, Padilla F, Barrabes JA, Pina P et al. (2002). Effect of inhibition of Na(+)/Ca(2+) exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res 55: 739-748.
71. Jones SP, Bolli R (2006). The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40: 16-23.
72. Kato T, Muraski J, Chen Y, Tsujita Y, Wall J, Glembotski CC et al. (2005). Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 115: 2716-2730.
73. Kitakaze M, Asakura M, Jiyoong K, Shintani Y, Asanuma H, Seguchi O et al. (2006). Evidence for human atrial natriuretic peptide and nicorandil as an adjunct to reperfusion therapy for acute myocardial infarction with ST-segment elevation: the randomized J-WIND (Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage) Trials. Circulation 114: 2425-2426 (abstract).
74. Kloner RA, Speakman MT, Przyklenk K (2002). Ischemic preconditioning: a plea for rationally targeted clinical trials. Cardiovasc Res 55: 526-533.
75. Kodani E, Xuan YT, Takano H, Shinmura K, Tang XL, Bolli R (2002). Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits. Circulation 105: 3046-3052.
76. Kojda G, Kottenberg K (1999). Regulation of basal myocardial function by nitric oxide. Cardiovasc Res 41: 514-523.
77. Kuhn M (2004). Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol 99: 76-82.
78. Kukreja RC (2007). Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase. Br J Pharmacol 150: 538-540.
79. Kuo JF, Greengard P (1970). Cyclic nucleotide-dependent protein kinases. VI. Isolation and partial purification of a protein kinase activated by guanosine 30,50-monophosphate. J Biol Chem 245: 2493-2498.
80. Kuo JF, Krueger BK, Sanes JR, Greengard P (1970). Cyclic nucleotide-dependent protein kinases. V. Preparation and properties of adenosine 3′,5′-monophosphate-dependent protein kinase from various bovine tissues. Biochim Biophys Acta 212: 79-91.
81. Kwan HY, Huang Y, Yao X (2000). Store-operated calcium entry in vascular endothelial cells is inhibited by cGMP via a protein kinase G-dependent mechanism. J Biol Chem 275: 6758-6763.
82. Layland J, Li JM, Shah AM (2002). Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol 540: 457-467.
83. Lellouche N, Tissier R, Souktani R, Giudicelli JF, Berdeaux A, Ghaleh B (2002). Reperfusion duration paradox with late myocardial preconditioning in rabbits. Eur J Pharmacol 450: 179-182.
84. Liao JK, Laufs U (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118.
85. Lincoln TM, Dey N, Sellak H (2001). Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 91: 1421-1430.
86. Liu GL, Christopher TA, Lopez BL, Gao F, Guo Y, Gao E et al. (1998). SP/W-5186, a cysteine-containing nitric oxide donor, attenuates postischemic myocardial injury. J Pharmacol Exp Ther 287: 527-537.
87. Lochner A, Genade S, Tromp E, Opie L, Moolman J, Thomas S et al. (1998). Role of cyclic nucleotide phosphodiesterases in ischemic preconditioning. Mol Cell Biochem 186: 169-175.
88. Lochner A, Marais E, Du Toit E, Moolman J (2002). Nitric oxide triggers classic ischemic preconditioning. Ann NY Acad Sci 962: 402-414.
89. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR (1997). Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 22: 307-312.
90. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S et al. (2000). Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52: 375-414.
91. Ma XL, Gao F, Liu GL, Lopez BL, Christopher TA, Fukuto JM et al. (1999). Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Proc Natl Acad Sci USA 96: 14617-14622.
92. Maejima Y, Adachi S, Ito H, Nobori K, Tamamori-Adachi M, Isobe M (2003). Nitric oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulating cyclin A-associated kinase activity. Cardiovasc Res 59: 308-320.
93. Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M (2005). Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol 38: 163-174.
94. Mathers CD, Loncar D (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: 442.
95. Mendelsohn ME (2005). Viagra: now mending hearts. Nat Med 11: 115-116.
96. Mocanu MM, Yellon DM (2007). PTEN: the Achilles' heel of myocardial ischaemia/reperfusin injury? Br J Pharmacol 150: 833-838.
97. Murry CE, Jennings RB, Reimer KA (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.
98. Nakano A, Liu GS, Heusch G, Downey JM, Cohen MV (2000). Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol 32: 1159-1167.
99. Nara M, Dhulipala PD, Ji GJ, Kamasani UR, Wang YX, Matalon S et al. (2000). Guanylyl cyclase stimulatory coupling to K(Ca) channels. Am J Physiol Cell Physiol 279: 1938-1945.
100. Nishikimi T, Maeda N, Matsuoka H (2006). The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69: 318-328.
101. Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002). Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283: 1263-1269.
102. Okamoto F, Allen BS, Buckberg GD, Bugyi H, Leaf J (1986). Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg 92: 613-620.
103. Okawa H, Horimoto H, Mieno S, Nomura Y, Yoshida M, Shinjiro S (2003). Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts. Mol Cell Biochem 248: 171-177.
104. ATP channel opening and leads to cardioprotection. Am J Physiol 286: 468-476.
105. ATP channel opener and a nitric oxide donor mimics ischaemic preconditioning. Clin Exp Pharmacol Physiol 30: 684-693.
106. Pabla R, Bland-Ward P, Moore PK, Curtis MJ (1995). An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart. Br J Pharmacol 116: 2923-2930.
107. Pabla R, Curtis MJ (1996). Endogenous protection against reperfusion-induced ventricular fibrillation: role of neuronal versus non-neuronal sources of nitric oxide and species dependence in the rat versus rabbit isolated heart. J Mol Cell Cardiol 28: 2097-2110.
108. Padilla F, Garcia-Dorado D, Agullo L, Barrabes JA, Inserte J, Escalona N et al. (2001). Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 51: 592-600.
109. Pagliaro P, Mancardi D, Rastaldo R, Penna C, Gattullo D, Miranda KM et al. (2003). Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med 34: 33-43.
110. Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D et al. (2006). Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 101: 168-179.
111. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C et al. (1998). Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 17: 3045-3051.
112. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M, Rich TC (2006). Natriuretic peptides and nitric oxide stimulates cGMP synthesis in different cellular compartments. J Gen Physiol 128: 3-14.
113. Piper HM, Abdallah Y, Schafer C (2004). The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61: 365-371.
114. Piper HM, Garcia-Dorado D (1999). Prime causes of rapid cardiomyocyte death during reperfusion. Ann Thorac Surg 68: 1913-1919.
115. Piper HM, Garcia-Dorado D, Ovize M (1998). A fresh look at reperfusion injury. Cardiovasc Res 38: 291-300.
116. Pollack M, Leeuwenburgh C (2001). Apoptosis and aging: role of the mitochondria. J Gerontol A Biol Sci Med Sci 56: 475-482.
117. ATP-dependent mechanism. Am J Physiol Heart Circ Physiol 287: 712-718.
118. Rabkin SW, Kong JY (2000). Nitroprusside induces cardiomyocyte death: interaction with hydrogen peroxide. Am J Physiol Heart Circ Physiol 279: 3089-3100.
119. Razavi HM, Hamilton JA, Feng Q (2005). Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 106: 147-162.
120. Ren B, Shen Y, Shao H, Qian J, Wu H, Jing H (2007). Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats. Clin Chim Acta 377: 83-87.
121. 2+ influx in reperfusion injury of metabolically inhibited cardiac myocytes. Cardiovasc Res 67: 291-300.
122. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH et al. (2006). Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 20: 27-36.
123. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291.
124. Salloum F, Yin C, Xi L, Kukreja RC (2003). Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92: 595-597.
125. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K et al. (2007). Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 42: 453-458.
126. Sato H, Jordan JE, Zhao ZQ, Sarvotham SS, Vinten-Johansen J (1997). Gradual reperfusion reduces infarct size and endothelial injury but augments neutrophil accumulation. Ann Thorac Surg 64: 1099-1107.
127. Satoh S, Makino N (2001). Intracellular mechanisms of cGMP-mediated regulation of myocardial contraction. Basic Res Cardiol 96: 652-658.
128. Schulz R, Kelm M, Heusch G (2004). Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 61: 402-413.
129. Scotland RS, Ahluwalia A, Hobbs AJ (2005). C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 105: 85-93.
130. Shimojo T, Hiroe M, Ishiyama S, Ito H, Nishikawa T, Marumo F (1999). Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Exp Cell Res 247: 38-47.
131. Simoons ML, Boersma E, Maas AC, Deckers JW (1997). Management of myocardial infarction: the proper priorities. Eur Heart J 18: 896-899.
132. Song W, Lu X, Feng Q (2000). Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res 45: 595-602.
133. Stefanelli C, Pignatti C, Tantini B, Stanic I, Bonavita F, Muscari C et al. (1999). Nitric oxide can function as either a killer molecule or an antiapoptotic effector in cardiomyocytes. Biochim Biophys Acta 1450: 406-413.
134. Su J, Scholz PM, Weiss HR (2005). Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med 230: 242-250.
135. Suematsu Y, Ohtsuka T, Hirata Y, Maeda K, Imanaka K, Takamoto S (2001). L-Arginine given after ischaemic preconditioning can enhance cardioprotection in isolated rat hearts. Eur J Cardiothorac Surg 19: 873-879.
136. Suenobu N, Shichiri M, Iwashina M, Marumo F, Hirata Y (1999). Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol 19: 140-146.
137. Szilvassy Z, Ferdinandy P, Bor P, Jakab I, Lonovics J, Koltai M (1994). Ventricular overdrive pacing-induced anti-ischemic effect: a conscious rabbit model of preconditioning. Am J Physiol 266: 2033-2041.
138. Szilvassy Z, Ferdinandy P, Szilvassy J, Nagy I, Karcsu S, Lonovics J et al. (1995). The loss of pacing-induced preconditioning in atherosclerotic rabbits: role of hypercholesterolaemia. J Mol Cell Cardiol 27: 2559-2569.
139. Szilvassy Z, Jakab I, Ferdinandy P, Koltai M, Lonovics J, Tarrade T et al. (1993). Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits. Life Sci 53: PL13-PL18.
140. Taimor G, Hofstaetter B, Piper HM (2000). Apoptosis induction by nitric oxide in adult cardiomyocytes via cGMP-signaling and its impairment after simulated ischemia. Cardiovasc Res 45: 588-594.
141. Takasago T, Imagawa T, Furukawa K, Ogurusu T, Shigekawa M (1991). Regulation of the cardiac ryanodine receptor by protein kinase-dependent phosphorylation. J Biochem (Tokyo) 109: 163-170.
142. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. (2005). Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222.
143. Takuma K, Phuagphong P, Lee E, Mori K, Baba A, Matsuda T (2001). Anti-apoptotic effect of cGMP in cultured astrocytes: inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore. J Biol Chem 276: 48093-48099.
144. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004). Postconditioning: a form of 'modified reperfusion' protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232.
145. Tsang A, Hausenloy DJ, Yellon DM (2005). Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol 289: 2-7.
146. Uchiyama T, Otani H, Okada T, Ninomiya H, Kido M, Imamura H et al. (2002). Nitric oxide induces caspase-dependent apoptosis and necrosis in neonatal rat cardiomyocytes. J Mol Cell Cardiol 34: 1049-1061.
147. Vegh A, Papp JG, Szekeres L, Parratt JR (1993). Prevention by an inhibitor of the L-arginine-nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogs. Br J Pharmacol 110: 18-19.
148. Vinten-Johansen J, Buckberg GD, Okamoto F, Rosenkranz ER, Bugyi H, Leaf J (1986). Superiority of surgical versus medical reperfusion after regional ischemia. J Thorac Cardiovasc Surg 92: 525-534.
149. Vittone L, Mundina-Weilenmann C, Said M, Ferrero P, Mattiazzi A (2002). Time course and mechanisms of phosphorylation of phospholamban residues in ischemia-reperfused rat hearts. Dissociation of phospholamban phosphorylation pathways. J Mol Cell Cardiol 34: 39-50.
150. Wall ME, Francis SH, Corbin JD, Grimes K, Richie-Jannetta R, Kotera J et al. (2003). Mechanisms associated with cGMP binding and activation of cGMP-dependent protein kinase. Proc Natl Acad Sci USA 100: 2380-2385.
151. Wanstall JC, Homer KL, Doggrell SA (2005). Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol 3: 41-53.
152. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K et al. (2004). Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44: 348-355.
153. + channels in the cardiac inner mitochondrial membrane. Science 298: 1029-1033.
154. ATP channels, and ERK. Am J Physiol Heart Circ Physiol 286: 1433-1440.
155. Yang XM, Philipp S, Downey JM, Cohen MV (2005). Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100: 57-63.
156. Yang XM, Philipp S, Downey JM, Cohen MV (2006). Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 101: 311-318.
157. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004). Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44: 1103-1110.
158. Yellon DM, Baxter GF (2000). Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? Heart 83: 381-387.
159. Yellon DM, Baxter GF, Garcia-Dorado D, Heusch G, Sumeray MS (1998). Ischaemic preconditioning: present position and future directions. Cardiovasc Res 37: 21-33.
160. Yellon DM, Downey JM (2003). Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113-1151.
161. Zhang Q, Scholz PM, He Y, Tse J, Weiss HR (2005). Cyclic GMP signaling and regulation of SERCA activity during cardiac myocyte contraction. Cell Calcium 37: 259-266.
162. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA et al. (2003). Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: 579-588.
163. Zhu B, Strada S, Stevens T (2005). Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 289: L196-L206.
164. 2+ extrusion through localized elevation of cGMP. J Biol Chem 275: 25892-25899.
165. Zucchi R, Ronca F, Ronca-Testoni S (2001). Modulation of sarcoplasmic